<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01387321</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719X1101</org_study_id>
    <nct_id>NCT01387321</nct_id>
  </id_info>
  <brief_title>A Study of BYL719 in Adult Patients With Advanced Solid Malignancies</brief_title>
  <official_title>A Study of BYL719 in Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      In this study, BYL719 will be administered to adult patients with advanced solid tumors whose
      disease has progressed despite standard therapy or for whom no standard therapy exists. The
      trial will investigate the safety and tolerability and determine the MTD of BYL719 in
      Japanese patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>4 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by type, frequency and severity of adverse events</measure>
    <time_frame>4 Months</time_frame>
    <description>Patients may continue treatment with BYL719 until the patient experiences unacceptable toxicity or progressive disease, an expected average of 4 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by RECIST</measure>
    <time_frame>4 months</time_frame>
    <description>Patients may continue treatment with BYL719 until the patient experiences unacceptable toxicity or progressive disease, an expected average of 4 months.
RECIST - Response Evaluation Criteria In Solid Tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PK Profiles (AUC, Cmax, Tmax, CL/F, Vz/F, T1/2)</measure>
    <time_frame>4 months</time_frame>
    <description>Patients may continue treatment with BYL719 until the patient experiences unacceptable toxicity or progressive disease, an expected average of 4 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of biomarkers in tumor and skin</measure>
    <time_frame>4 months</time_frame>
    <description>Patients may continue treatment with BYL719 until the patient experiences unacceptable toxicity or progressive disease, an expected average of 4 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>BYL719</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <arm_group_label>BYL719</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically-confirmed, advanced unresectable solid tumors
             Availability of a representative formalin fixed paraffin embedded tumor tissue sample

          -  At least one measurable or non-measurable lesion Age ≥ 18 years

          -  Eastern Cooperative Oncology Group(ECOG) Performance Status ≤ 2 Good organ (hepatic,
             kidney, BM) function at screening/baseline visit

        Exclusion Criteria:

          -  Brain metastasis unless treated and free of signs/symptoms attributable to brain
             metastasis in the absence of corticosteroid therapy and anti-epileptic therapy.

          -  Prior treatment with PI3K inhibitor

          -  Patient with peripheral neuropathy NCI-CTC Grade ≥ 2

          -  Patient with diarrhea NCI-CTC Grade ≥ 2

          -  Patient with acute or chronic pancreatitis

          -  Impaired cardiac function or clinically significant cardiac disease incl unstable
             angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial
             Infarction (AMI) ≤ 3 months prior to starting study drug

          -  Patients with clinically manifest diabetes mellitus, history of gestational diabetes
             mellitus or documented steroid-induced diabetes mellitus

          -  Women who are pregnant or breast feeding or adults of reproductive potential not
             employing an effective method of birth control

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2011</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pi3K</keyword>
  <keyword>Advanced solid tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

